[CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
D000368:Aged; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects
D004791:Enzyme Inhibitors; D004873:Ergolines; D011954:Receptors, Dopamine; D007980:Levodopa; D002262:Carboxy-Lyases
Le CB 154 dans le traitement de la maladie de Parkinson. Résultats d'une association avec la L-DOPA + IDD